ALSO NOTED: CoGenesys licenses VEGF rights; Oscient completes Antara buyout; and much more...

> Upstart biotech CoGenesys has inked a licensing deal with Australia's Vegenics covering the rights to intellectual property in the field of vascular endothelial growth factors. Report

> Oscient Pharmaceuticals has completed the buyout of Reliant Pharmaceuticals' cholesterol drug Antara. Report

> The UK's drug watchdog, NICE, has concluded that a bowel cancer therapy--Cetuximab--does not represent a good use of health dollars. Data suggests the drug extends the lives of cancer patients by about five months. Article

> Human Pheromone Sciences has inked a licensing deal with a Johnson & Johnson subsidiary regarding "certain patents." Report

> MedImmune has filed an INDA for a new therapy for lymphoma. Report

> Dainippon Sumitomo and Pfizer have settled a lawsuit over a licensing deal regarding Amlodin. Report

> Isotechnika announced that an experimental therapy to prevent organ rejection appeared safe in Phase I. Report

And Finally… Human Growth Hormone therapy has been catching on in the U.S., despite the fact that it's illegal and there is clinical data to suggest it may end up damaging many people's health. Report